Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries

Clinical Therapeutics

Volumn 36, Issue 9, 2014, Pages 1160-1168

  Cotté, Franҫois Emery ^a   Benhaddi, Hicham ^a   Duprat Lomon, Isabelle ^a   Doble, Adam ^b   Marchant, Nick ^c   Letierce, Alexia ^d   Huguet, Michael ^d  

^a BRISTOL MYERS SQUIBB   (United States)

^b Foxymed   (France)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d Cegedim Strategic Data ^*  (France)

Author keywords

Anticoagulation; Atrial fibrillation; Hemorrhage; Stroke; Vitamin K antagonist; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BLOOD CLOTTING TIME; DRUG MONITORING; FACTUAL DATABASE; FEMALE; FRANCE; GERMANY; HEMORRHAGE; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; ITALY; MALE; MIDDLE AGED; RISK FACTOR; STROKE; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; DATABASES, FACTUAL; DRUG MONITORING; FEMALE; FIBRINOLYTIC AGENTS; FRANCE; GERMANY; GREAT BRITAIN; HEMORRHAGE; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; ITALY; MALE; MIDDLE AGED; RISK FACTORS; STROKE; VITAMIN K; WHOLE BLOOD COAGULATION TIME; YOUNG ADULT;

EID: 84908702602     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.07.016     Document Type: Article

References (44)

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
2. Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Eur Soc Cardiol. 2013;15:486-493.
3. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.
4. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
5. Charlemagne A, Blacher J, Cohen A, et al. Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data. Arch Cardiovasc Dis. 2011;104:115-124.
6. Meinertz T, Kirch W, Rosin L, et al. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol. 2011;100:897-905.
7. Piccinocchi G, Laringe M, Guillaro B, et al. Diagnosis and management of atrial fibrillation by primary care physicians in Italy: a retrospective, observational analysis. Clin Drug Invest. 2012;32:771-777.
8. Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001;86:516-521.
9. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998;352:1167-1171.
10. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952.
11. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation. 2012;126:e143-e146.
12. Tendera M, Syzdol M, Parma Z. ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? Cardiol J. 2012;19:4-10.
13. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
14. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):546S-592S.
15. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115-1119.
16. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449-1457.
17. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S-e5375.
18. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-2870.
19. Camm AJ, Lip GY, De Caterina R, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. ∗Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
20. Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172-1179.
21. Gorin L, Fauchier L, Nonin E, et al. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest. 2011;140:911-917.
22. Lin LJ, Cheng MH, Lee CH, et al. Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-a nationwide descriptive study in Taiwan. Clin Ther. 2008;30:1726-1736.
23. Nieuwlaat R, Olsson SB, Lip GY, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J. 2007;153:1006-1012.
24. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarinassociated intracranial and extracranial hemorrhages. Am J Med. 2007;120:700-705.
25. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-1451.
26. Gallego P, Vilchez JA, Lane DA. Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range. Circulation. 2013;127:2163-2165.
27. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109:569-579.
28. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost. 2011;106:968-977.
29. Phillips KW, Ansell J. Outpatient management of oral vitamin K antagonist therapy: defining and measuring high-quality management. Exp Rev Cardiovasc Ther. 2008;6:57-70.
30. Pereira de Sousa L, Burba I, Ruperto C, et al. Vitamin K antagonists in patients with nonvalvular atrial fibrillation: appropriateness and quality of treatment in an Italian cohort. J Cardiovasc Med (Hagerstown). 2013;14:534-540.
31. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circulation Cardiovascular Quality and Outcomes. 2008;1:84-91.
32. Bouee S, Charlemagne A, Fagnani F, et al. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine. 2004;71:214-220.
33. Cotte FE, Fardellone P, Mercier F, et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010;21:145-155.
34. Cea Soriano L, Bateman BT, Garcia Rodriguez LA, et al. Prescription of antihypertensive medications during pregnancy in the UK. Pharmacoepidemiol Drug Safe. 2014.
35. Mazzaglia G, Filippi A, Alacqua M, et al. A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care. Thromb Haemost. 2010;103:968-975.
36. Sabouret P, Depret-Bixio L, Cotte FE, et al. Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) Database. Clin Res Cardiol. 2014.
37. Rosendaal FR, Cannegieter SC, van der Meer FJ, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239.
38. Lader E, Martin N, Cohen G, et al. Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do? J Clin Pharm Ther. 2012;37:375-377.
39. Poli D, Testa S, Antonucci E, et al. Bleeding and stroke risk in a realworld prospective primary prevention cohort of patients with atrial fibrillation. Chest. 2011;140:918-924.
40. Cohen A, Dallongeville J, Durand-Zaleski I, et al. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis. 2010;103:376-387.
41. Reinhold T, Rosenfeld S, Muller-Riemenschneider F, et al. [Patients suffering from atrial fibrillation in Germany. Characteristics, resource consumption and costs]. Herz. 2012;37:534-542.
42. Zoni-Berisso M, Filippi A, Landolina M, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study). Am J Cardiol. 2013;111:705-711.
43. Gallagher AM, van Staa TP, Murray-Thomas T, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open. 2014;4:e003839.
44. Cotte FE, Chaize G, Kachaner I, et al. Incidence and cost of stroke and hemorrhage in patients diagnosed with atrial fibrillation in France. J Stroke Cerebrovasc Dis. 2014;23:e73-e83.